Cited by 108Monoclonal and Polyclonal Antibodies ResearchBarrier Structure and Function StudiesDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

Open access

Garg, Amit, Balthasar, Joseph P.·2009·The AAPS Journal

DOI 10.1208/s12248-009-9129-9PMC PMC2758122

Open this paper in CoChat — free account Open PDF

Abstract

It has been suggested that the neonatal Fc receptor (FcRn) is a primary determinant of the distribution of IgG to the brain. In the present report, (125)I-labeled 7E3, a monoclonal IgG1 antibody, was injected intravenously to groups of FcRn-deficient mice and C57BL/6J control mice. Sub-groups of three mice were sacrificed at several time points. Blood and brain tissue were harvested and radioactivity was assessed. Antibody concentrations in brain were corrected for residual blood using (51)Cr-labeled red blood cells. Data were analyzed via WinNonlin, and areas under plasma and tissue concentration vs. time curves (AUCs) were assessed via the Bailer method. The apparent plasma elimination half-life and clearance of 7E3 were 13.61 +/- 0.61 days and 6.5 +/- 0.10 ml/day/kg in control mice and 0.70 +/- 0.05 days and 63.5 +/- 2.7 ml/day/kg in the knockout mice. Plasma and brain AUCs (0-10 days) were found to be 3,338.7 +/- 50.4 and 7.46 +/- 0.5 nM day in control animals and 781.2 +/- 16.6 and 1.65 +/- 0.1 nM day in FcRn-deficient animals. There was no significant difference between brain-to-plasma AUC ratios in control and FcRn-deficient mice (0.0022 +/- 0.00015 vs. 0.0021 +/- 0.00011, p = 0.3347). Two-way analysis of variance showed no significant differences, at any time point, between brain-to-plasma concentration ratios determined from control and knockout animals. The results suggest that FcRn does not contribute significantly to the "blood-brain barrier" for IgG in mice, and the data suggest that FcRn is not responsible for the low exposure of IgG in the brain relative to plasma.

Integrity signals

Registry

Crossref · 10.1208/s12248-009-9129-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,408
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,265
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 696
Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice
Ghetie, V. F., Hubbard, J. G., Kim, J., Tsen, M. F., Lee, Y., & Ward, E. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260327 · Cited by 478
A Theoretical Model of γ-Globulin Catabolism
Brambell, F. W. R., Hemmings, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 461
The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs
Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S. B., Avanessian, L., Choi, E. Y., Shaffer, D. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3528 · Cited by 454
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line
Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 433
Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life
Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 413

Show all 42 references

Sorted by citations

From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport
Wevers, N. R., Kasi, D. G., Gray, T., Wilschut, K. J., Smith, B., van Vught, R., Shimizu, F., Sano, Y., Kanda, T., Marsh, G. A., et al. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0108-3 · Cited by 373
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Healthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 319
Designing antibodies as therapeutics
Carter, P. J., & Rajpal, A. (2022) · Cell · doi:10.1016/j.cell.2022.05.029 · Cited by 282
Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
Shah, D. K., & Betts, A. M. (2013) · mAbs · doi:10.4161/mabs.23684 · Cited by 262
Neonatal Fc Receptor: From Immunity to Therapeutics
Kuo, T. T., Baker, K., Yoshida, M., Qiao, S., Aveson, V. G., Lencer, W. I., & Blumberg, R. S. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9468-4 · Cited by 258
Neonatal Fc receptor and IgG-based therapeutics
Kuo, T. T., & Aveson, V. G. (2011) · mAbs · doi:10.4161/mabs.3.5.16983 · Cited by 243
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 236
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00966-w · Cited by 218
“In preclinical species and humans, mAbs are known to have minimal brain penetration, at around 0.1–0.4% of mAb plasma concentration 35,36 .”
Influential
Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood–brain barrier
Hladky, S. B., & Barrand, M. A. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0113-6 · Cited by 206
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. L. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 171
Antibody therapies in CNS diseases
Freskgård, P., & Urich, E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.014 · Cited by 144
Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn
Cooper, P. R., Ciambrone, G. J., Kliwinski, C. M., Maze, E., Johnson, L., Li, Q., Feng, Y., & Hornby, P. J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.08.035 · Cited by 124
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
Niederalt, C., Kuepfer, L., Solodenko, J., Eißing, T., Siegmund, H., Block, M. S., Willmann, S., & Lippert, J. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9559-4 · Cited by 121
Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives
Kouhi, A., Pachipulusu, V., Kapenstein, T., Hu, P., Epstein, A. L., & Khawli, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126442 · Cited by 109
A comprehensive review of the neonatal Fc receptor and its application in drug delivery
Martins, J. P., Kennedy, P. J., Santos, H. A., Barrias, C. C., & Sarmento, B. F. C. C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.007 · Cited by 106
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Thomas, V. A., & Balthasar, J. P. (2019) · Antibodies · doi:10.3390/antib8040056 · Cited by 106
Self-citation
Transportation of Single-Domain Antibodies through the Blood–Brain Barrier
Ruiz-López, E., & Schuhmacher, A. J. (2021) · Biomolecules · doi:10.3390/biom11081131 · Cited by 104
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
Quantitative cumulative biodistribution of antibodies in mice
Yip, V., Palma, E., Tesar, D. B., Mundo, E. E., Bumbaca, D., Torres, E. K., Reyes, N. A., Shen, B., Fielder, P. J., Prabhu, S., et al. (2014) · mAbs · doi:10.4161/mabs.28254 · Cited by 88
Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration
Pepinsky, R. B., Shao, Z., Ji, B., Wang, Q., Meng, G., Walus, L. R., Lee, X., Hu, Y., Graff, C. P., Garber, E. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183483 · Cited by 90
Antibody pharmacokinetics in rat brain determined using microdialysis
Chang, H.-Y., Morrow, K., Bonacquisti, E. E., Zhang, W., & Shah, D. K. (2018) · mAbs · doi:10.1080/19420862.2018.1473910 · Cited by 87
A translational platform PBPK model for antibody disposition in the brain
Chang, H.-Y., Wu, S., Meno‐Tetang, G. M. L., & Shah, D. K. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09641-8 · Cited by 87
FcRn: From Molecular Interactions to Regulation of IgG Pharmacokinetics and Functions
Challa, D. K., Velmurugan, R., Ober, R. J., & Ward, E. S. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_12 · Cited by 88
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis
Edavettal, S. C., Cejudo–Martín, P., Dasgupta, B., Yang, D., Buschman, M. D., Domingo, D. L., Kolen, K. V., Jaiprasart, P., Gordon, R. E., Schutsky, K., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.007 · Cited by 86
Investigation of the Role of FcγR and FcRn in mAb Distribution to the Brain
Abuqayyas, L., & Balthasar, J. P. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300214k · Cited by 77
Self-citation
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
Kielbasa, W., & Helton, D. (2019) · Cephalalgia · doi:10.1177/0333102419840780 · Cited by 74
High-Throughput Method Development for Sensitive, Accurate, and Reproducible Quantification of Therapeutic Monoclonal Antibodies in Tissues Using Orthogonal Array Optimization and Nano Liquid Chromatography/Selected Reaction Monitoring Mass Spectrometry
Duan, X., Abuqayyas, L., Dai, L.-P., Balthasar, J. P., & Qu, J. (2012) · Analytical Chemistry · doi:10.1021/ac2034166 · Cited by 73
Self-citation
Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration
Wang, Q., Delva, L., Weinreb, P. H., Pepinsky, R. B., Graham, D. L., Veizaj, E., Cheung, A. E., Chen, W., Nestorov, I. A., Rohde, E., et al. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0093-6 · Cited by 71
Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier
Gelb, S., Stock, A. D., Anzi, S., Putterman, C., & Ben‐Zvi, A. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.03.001 · Cited by 73
Deciphering albumin-directed drug delivery by imaging
Hu, H., Quintana, J. M., Weissleder, R., Parangi, S., & Miller, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114237 · Cited by 71
Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview
Chowdhury, E. A., Noorani, B., Alqahtani, F., Bhalerao, A., Raut, S., Sivandzade, F., & Cucullo, L. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20985946 · Cited by 77
Toward Sensitive and Accurate Analysis of Antibody Biotherapeutics by Liquid Chromatography Coupled with Mass Spectrometry
An, B., Zhang, M., & Qu, J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058917 · Cited by 61
Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn
Ruano-Salguero, J. S., & Lee, K. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60438-z · Cited by 63
Nutritional value, bioactivity, and application potential of Jerusalem artichoke (Helianthus tuberosus L.) as a neotype feed resource
Wang, Y., Zhao, Y., Xue, F., Nan, X., Wang, H., Hua, D., Liu, J., Yang, L., Jiang, L., & Xiong, B. (2020) · Animal nutrition · doi:10.1016/j.aninu.2020.09.001 · Cited by 59
The effect of the neonatal Fc receptor on human IgG biodistribution in mice
Chen, N., Wang, W., Fauty, S. E., Fang, Y., Hamuro, L., Hussain, A., & Prueksaritanont, T. (2014) · mAbs · doi:10.4161/mabs.27765 · Cited by 57
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 56
A differentiating neural stem cell-derived astrocytic population mitigates the inflammatory effects of TNF-α and IL-6 in an iPSC-based blood-brain barrier model
Mantle, J. L., & Lee, K. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.07.030 · Cited by 52
Neonatal Fc Receptor–Targeted Therapies in Neurology
Nelke, C., Spatola, M., Schroeter, C. B., Wiendl, H., & Lünemann, J. D. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01175-7 · Cited by 48
Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations
Chang, H., Kim, S. J., & Shah, D. K. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.05.025 · Cited by 48
Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis
Buck, D., Albrecht, E., Aslam, M., Goris, A., Hauenstein, N., Jochim, A., Cepok, S., Grummel, V., Dubois, B., Berthele, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23749 · Cited by 48
Assessments of antibody biodistribution
Glassman, P. M., Abuqayyas, L., & Balthasar, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.365 · Cited by 42
Self-citation
Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Rocha, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990613 · Cited by 42
Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis
Chang, H.-Y., Wu, S., Li, Y., Zhang, W., Burrell, M. R., Webster, C. I., & Shah, D. K. (2021) · mAbs · doi:10.1080/19420862.2021.1874121 · Cited by 42
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 43
Physical insights into the blood–brain barrier translocation mechanisms
Theodorakis, P. E., Müller, E. A., Craster, R. V., & Matar, O. K. (2017) · Physical Biology · doi:10.1088/1478-3975/aa708a · Cited by 40
The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation
Conner, K. P., Devanaboyina, S. C., Thomas, V. A., & Rock, D. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107574 · Cited by 39
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 42
Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?
Ladel, S., Flamm, J., Zadeh, A. S., Filzwieser, D., Walter, J.-C., Schlossbauer, P., Kinscherf, R., Lischka, K., Luksch, H., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030107 · Cited by 36
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
Liu, C. M., Killion, E. A., Hammoud, R., Lu, S.-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V. A., Cook, K. D., Sivits, G. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01295-w · Cited by 37
Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody
Abuqayyas, L., & Balthasar, J. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.042 · Cited by 34
Self-citation
Quantification of Human Mabs in Mouse Tissues Using Generic Affinity Enrichment Procedures and LC–MS Detection
Sleczka, B. G., Mehl, J. T., Shuster, D. J., Lewis, K. E., Moore, R., Vuppugalla, R., Rajendran, S., D’Arienzo, C. J., & Olah, T. V. (2014) · Bioanalysis · doi:10.4155/bio.14.143 · Cited by 28
Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice
Fan, Y., Avery, L. B., Wang, M., O’Hara, D. M., Leung, S. S., & Neubert, H. (2016) · mAbs · doi:10.1080/19420862.2016.1178436 · Cited by 28
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
Tien, J., Leonoudakis, D., Petrova, R., Trinh, V., Taura, T., Sengupta, D., Jo, L., Sho, A., Yun, Y. G., Doan, E., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2229098 · Cited by 28
Structure of the LINGO-1–Anti-LINGO-1 Li81 Antibody Complex Provides Insights into the Biology of LINGO-1 and the Mechanism of Action of the Antibody Therapy
Pepinsky, R. B., Arndt, J. W., Quan, C., Gao, Y. L., Quintero‐Monzon, O., Lee, X., & Mi, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211771 · Cited by 26
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
Ménochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 25
Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa
Ladel, S., Maigler, F., Flamm, J., Schlossbauer, P., Handl, A., Hermann, R., Herzog, H., Hummel, T. R., Mizaikoff, B., & Schindowski, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111014 · Cited by 23
Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy
Finke, J. M., & Banks, W. A. (2016) · Human Antibodies · doi:10.3233/hab-160306 · Cited by 23
Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
Zakrzewicz, A., Würth, C., Beckert, B., Feldhoff, S., Vanderheyden, K., Foss, S., Andersen, J. T., de Haard, H., Verheesen, P., Bobkov, V., et al. (2022) · Cells · doi:10.3390/cells11060942 · Cited by 23
Antibody blood-brain barrier efflux is modulated by glycan modification
Finke, J. M., Ayres, K. R., Brisbin, R., Hill, H. A., Wing, E. E., & Banks, W. A. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.008 · Cited by 22
Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
Schwinghamer, K., & Siahaan, T. J. (2023) · Journal of Nanotheranostics · doi:10.3390/jnt4040020 · Cited by 21
Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound
Jusko, W. J., Molins, E. A. G., & Ayyar, V. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000118 · Cited by 20
Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations
Huang, X., Zheng, F., & Zhan, C. (2013) · Molecular BioSystems · doi:10.1039/c3mb70231f · Cited by 17
In Vitro and In Vivo Methods for Assessing FcRn-Mediated Reverse Transcytosis Across the Blood–Brain Barrier
Caram‐Salas, N. L., Boileau, E., Farrington, G. K., Garber, E. A., Brunette, E., Abulrob, A., & Stanimirovic, D. B. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-191-8_26 · Cited by 17
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody
Schlein, E., Andersson, K. G., Dallas, T. D., Syvänen, S., & Sehlin, D. (2024) · mAbs · doi:10.1080/19420862.2024.2339337 · Cited by 18
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 16
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity
Ait‐Oudhia, S., Ovacik, M., & Mager, D. E. (2016) · mAbs · doi:10.1080/19420862.2016.1238995 · Cited by 14
A new technology for increasing therapeutic protein levels in the brain over extended periods
Nakano, R., Takagi‐Maeda, S., Ito, Y., Kishimoto, S., Osato, T., Noguchi, K., Kurihara-Suda, K., & Takahashi, N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214404 · Cited by 15
Investigation of Antibody Pharmacokinetics in the Brain Following Intra-CNS Administration and Development of PBPK Model to Characterize the Data
Wu, S., Chang, H.-Y., Chowdhury, E. A., Huang, H. W., & Shah, D. K. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00898-7 · Cited by 14
Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer
Thomas, V. A., & Balthasar, J. P. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9909-y · Cited by 13
Self-citation
A Popperian View on Anti‐CGRP Biologics in Migraine
Chiarugi, A. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13695 · Cited by 13
Exit pathways of therapeutic antibodies from the brain and retention strategies
Schellhammer, L., Beffinger, M., Salazar, U., Laman, J. D., Buch, T., & Berg, J. V. (2023) · iScience · doi:10.1016/j.isci.2023.108132 · Cited by 14
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data
Wu, S., Prieult, F. L., Phipps, C. J., Mezler, M., & Shah, D. K. (2022) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-022-09823-x · Cited by 13
Toward Accurate and Robust Liquid Chromatography–Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in Tissues
An, B., Zhang, M., Pu, J., Qu, Y., Shen, S., Zhou, S., Ferrari, L., Vazvaei, F., & Qu, J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03620 · Cited by 11
Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 11
Exploring How Antibody Format Drives Clearance from the Brain
Schwinghamer, K., Kopec, B. M., Ayewoh, E. N., Tao, X., Sadekar, S., Sreedhara, A., Kelley, R. F., Tesar, D. B., & Siahaan, T. J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00354 · Cited by 10
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
De Sutter, P.-J., Gasthuys, E., & Vermeulen, A. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09894-4 · Cited by 8
The FcRn from gene to protein and function: comparison between species
Ortiz-Alegría, L. B., Xicoténcatl-García, L., Cañedo-Solares, I., Rico-Torres, C. P., & Gómez‐Chávez, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608426 · Cited by 6
Protective effects of an anti‐melanocortin‐4 receptor scFv derivative in lipopolysaccharide‐induced cachexia in rats
Peter, J., Rossez, H., Weckering, M., Zipfel, G., Lecourt, A.-C., Owen, J. B., Banks, W. A., & Hofbauer, K. G. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-012-0084-4 · Cited by 7
Proteomic analysis of age-related changes in ovine cerebrospinal fluid
Chen, C. P. C., Preston, J. E., Zhou, S., Fuller, H. R., Morgan, D. G. A., & Chen, R. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.04.012 · Cited by 6
Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice
Parra-Guillen, Z. P., Janda, Á., Alzuguren, P., Berraondo, P., Hernández-Alcoceba, R., & Trocóniz, I. F. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9423-9 · Cited by 6
Effect of FcRn Binding on Monoclonal Antibody Disposition in the Brain
Huang, H. W., Wu, S., Liu, S., & Shah, D. K. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01060-7 · Cited by 5
Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody
Wuensche, T. E., Stergiou, N., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Jensen, A. D., Asuni, A. A., Bang‐Andersen, B., van Dongen, G. A. M. S., et al. (2024) · Molecular Imaging and Biology · doi:10.1007/s11307-024-01931-z · Cited by 5
A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations
Puszkiel, A., Bousquet, G., Stanke‐Labesque, F., Stocco, J., Decq, P., Chevillard, L., Goutagny, S., & Declèves, X. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03614-w · Cited by 4
Truncation of the Murine Neonatal Fc Receptor Cytoplasmic Tail Does Not Alter IgG Metabolism or Transport In Vivo
Ma, Y., Ke, C., Wan, Z., Li, Z., Cheng, X., Wang, X., Zhao, J., Ma, Y., Ren, L., Han, H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700924 · Cited by 4
Maternal immunoglobulin G affects brain development of mouse offspring
Sadakata, M., Fujii, K., Kaneko, R., Hosoya, E., Sugimoto, H., Kawabata‐Iwakawa, R., Kasamatsu, T., Hongo, S., Koshidaka, Y., Takase, A., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03100-z · Cited by 4
Studies of Nontarget-Mediated Distribution of Human Full-Length IgG1 Antibody and Its FAb Fragment in Cardiovascular and Metabolic-Related Tissues
Davidsson, P., Söderling, A., Svensson, L., Ahnmark, A., Flodin, C., Wanag, E., Sundquist, V. S., & Gennemark, P. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24368 · Cited by 3
A long-lasting prolactin stimulates galactopoiesis in mice
Kready, K. M., Doiron, K. E., Chan, K. R., Way, J. C., Justman, Q. A., Powe, C. E., & Silver, P. A. (2025) · iScience · doi:10.1016/j.isci.2025.113112 · Cited by 2
Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations
Mahmood, I., & Tegenge, M. A. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.06.004 · Cited by 2
Quantitation of regional distribution of antibodies in rat brain following systemic and intra-CNS administration
Wu, S., Huang, H. W., Panchal, A., Chowdhury, E. A., & Shah, D. K. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251333536 · Cited by 1
Recombinant Production and Characterization of Par-4/SAC
Zheng, F., & Zhan, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80558-6_12 · Cited by 1
Pharmacokinetics of Immunoglobulin G and Serum Albumin: Impact of the Neonatal Fc Receptor on Drug Design
Andersen, J. T., & Sandlie, I. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch4 · Cited by 1
The Biology of the Neonatal Fc Receptor (FcRn)
Kim, J. (2012) · Wiley eBooks · doi:10.1002/9783527644827.ch8
Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier
Fricker, G., & Mahringer, A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse552
ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules
Wang, W., & Prueksaritanont, T. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse536
Approaches Towards Prediction of CNS PK and PD
de Lange, E. C. M., Chang, H. Y., & Shah, D. K. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_12
Increasing Brain Exposure of Antibodies
Lesuisse, D. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_2

Authors: Garg, A., & Balthasar, J. P.
Affiliations: University at Buffalo, State University of New York (US)
Corresponding author: Balthasar, Joseph P.
ORCID: Garg, Amit
Balthasar, Joseph P.
Venue: The AAPS Journal
Publisher: Springer Science and Business Media LLC
Published: 2009-07-28
Volume: 11
Issue: 3
Pages: 553-7
ISSN: 1550-7416 (ISSN-L)
DOI: 10.1208/s12248-009-9129-9
PMC: PMC2758122
OpenAlex: W2045301605
Cited by: 108
References: 42
Citations by year: 2026: 3 · 2025: 8 · 2024: 9 · 2023: 5 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 5 · 2018: 11 · 2017: 3 · 2016: 7 · 2015: 5 · 2014: 6 · 2013: 6 · 2012: 8
FWCI: 3.78
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: The AAPS Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Eli Lilly and Company
National Institutes of Health
National Institute of Allergy and Infectious Diseases (AI60687, R01AI060687)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: neonatal Fc receptor, IgG, brain distribution, blood-brain barrier, antibody clearance, plasma half-life, brain-to-plasma ratio, passive immunization
MeSH terms: Animals, beta 2-Microglobulin, Brain, Immunoglobulin G, Iodine Radioisotopes, Mice, Inbred C57BL, Receptors, Fc, Histocompatibility Antigens Class I, Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Investigation of the Influence of FcRn on the Distribution of IgG to the Brain

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks